Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$1.95 -5.8%	$1.68	$1.43 ▼ $4.41	$195.80M	1.57	152,378 shs	134,136 shs
CTMX CytomX Therapeutics	$2.75 -8.0%	$1.56	$0.40 ▼ $3.10	$221.71M	2.11	2.15 million shs	1.97 million shs
KRON Kronos Bio	$0.89 +1.4%	$0.78	$0.65 ▼ $1.60	$53.73M	1.63	344,865 shs	347,765 shs
MNPR Monopar Therapeutics	$33.52 -0.9%	$37.17	$1.72 ▼ $54.30	$204.98M	0.99	359,742 shs	41,799 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	-4.41%	+24.20%	-14.85%	-57.97%
CTMX CytomX Therapeutics	0.00%	+4.17%	+37.50%	+323.34%	+84.56%
KRON Kronos Bio	0.00%	+2.36%	+26.61%	-5.04%	-30.27%
MNPR Monopar Therapeutics	0.00%	-9.67%	-15.25%	+12.67%	+649.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.9891 of 5 stars	3.5	3.0	0.0	3.3	0.8	1.3
CTMX CytomX Therapeutics	4.2736 of 5 stars	3.5	1.0	4.7	2.6	2.5	1.3
KRON Kronos Bio	3.2534 of 5 stars	3.2	3.0	0.0	1.9	4.2	1.3
MNPR Monopar Therapeutics	2.861 of 5 stars	3.4	5.0	0.0	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	515.38% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	93.94% Upside
KRON Kronos Bio	2.33	Hold	$1.63	82.05% Upside
MNPR Monopar Therapeutics	2.75	Moderate Buy	$55.33	65.08% Upside

Current Analyst Ratings Breakdown

Latest KRON, CTMX, MNPR, and ACIU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/1/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
4/3/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/2/2025	MNPR Monopar Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/1/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/19/2025	MNPR Monopar Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$76.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$28.30M	6.92	N/A	N/A	$2.12 per share	0.92
CTMX CytomX Therapeutics	$147.56M	1.50	N/A	N/A	($0.71) per share	-3.87
KRON Kronos Bio	$9.19M	5.93	N/A	N/A	$2.73 per share	0.33
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$1.88 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$60.41M	-$0.58	N/A	N/A	N/A	N/A	-28.26%	-18.98%	8/5/2025 (Estimated)
CTMX CytomX Therapeutics	-$570K	$0.48	16.18	N/A	N/A	10.96%	-41.47%	8.11%	8/6/2025 (Estimated)
KRON Kronos Bio	-$112.67M	-$1.07	N/A	N/A	N/A	-867.66%	-64.55%	-48.18%	8/6/2025 (Estimated)
MNPR Monopar Therapeutics	-$8.40M	-$3.48	N/A	N/A	N/A	N/A	-107.21%	-87.57%	8/8/2025 (Estimated)

Latest KRON, CTMX, MNPR, and ACIU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
4/30/2025	Q1 2025	ACIU AC Immune	-$0.22	-$0.21	+$0.01	-$0.21	$1.99 million	$1.12 million
3/31/2025	Q4 2024	MNPR Monopar Therapeutics	-$0.36	-$2.23	-$1.87	-$2.23	N/A	N/A
3/18/2025	Q4 2024	KRON Kronos Bio	-$0.30	-$0.43	-$0.13	-$0.43	$1.00 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.86	1.86
CTMX CytomX Therapeutics	N/A	1.04	1.04
KRON Kronos Bio	N/A	8.32	8.32
MNPR Monopar Therapeutics	N/A	5.41	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
CTMX CytomX Therapeutics	67.77%
KRON Kronos Bio	64.09%
MNPR Monopar Therapeutics	1.83%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
CTMX CytomX Therapeutics	6.60%
KRON Kronos Bio	24.40%
MNPR Monopar Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	94.39 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
KRON Kronos Bio	100	61.05 million	45.62 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	3.97 million	Not Optionable

KRON, CTMX, MNPR, and ACIU Headlines

Recent News About These Companies

Monopar Therapeutics (NASDAQ:MNPR) Trading 0.4% Higher - Time to Buy?

June 12 at 2:09 AM | marketbeat.com

Monopar Therapeutics Inc.: Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | finanznachrichten.de

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know

June 11, 2025 | zacks.com

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | globenewswire.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Down 13.8% in May

June 5, 2025 | marketbeat.com

Monopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%

June 3, 2025 | msn.com

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

June 3, 2025 | globenewswire.com

Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Wall Street Zen

May 24, 2025 | marketbeat.com

Point72 Asset Management L.P. Takes Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)

May 23, 2025 | marketbeat.com

Janus Henderson Group PLC Invests $23.44 Million in Monopar Therapeutics Inc. (NASDAQ:MNPR)

May 18, 2025 | marketbeat.com

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 14, 2025 | manilatimes.net

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 13, 2025 | globenewswire.com

Monopar Therapeutics Presents Long-Term Efficacy and Safety Data for ALXN1840 in Wilson Disease at EASL International Liver Congress 2025

May 8, 2025 | nasdaq.com

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025 | globenewswire.com

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025

April 30, 2025 | insidermonkey.com

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

April 29, 2025 | globenewswire.com

Piper Sandler Remains a Buy on Monopar Therapeutics Inc (MNPR)

April 14, 2025 | markets.businessinsider.com

Why Monopar Therapeutics Inc.’s (MNPR) Stock Is Down 9.91%

April 10, 2025 | aaii.com

Why Monopar Therapeutics Inc.’s (MNPR) Stock Is Down 13.27%

April 5, 2025 | aaii.com

Tactic Pharma Llc Sells 33,334 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

April 5, 2025 | insidertrades.com

Monopar Therapeutics downgraded to Hold from Buy at JonesResearch

April 2, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRON, CTMX, MNPR, and ACIU Company Descriptions

AC Immune NASDAQ:ACIU

$1.95 -0.12 (-5.80%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.97 +0.02 (+1.03%)

As of 06/13/2025 07:50 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

CytomX Therapeutics NASDAQ:CTMX

$2.75 -0.24 (-8.03%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.84 +0.09 (+3.31%)

As of 06/13/2025 07:57 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Kronos Bio NASDAQ:KRON

$0.89 +0.01 (+1.43%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.88 -0.01 (-1.19%)

As of 06/13/2025 04:15 PM Eastern

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Monopar Therapeutics NASDAQ:MNPR

$33.52 -0.30 (-0.89%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$33.74 +0.22 (+0.66%)

As of 06/13/2025 06:12 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time